Further clinical characterization in PRAD was performed, with the results that the over-expression of POLG2 was related to pathologic T, pathologic N stage, Gleason score, PSA values, primary therapy outcome and clinical survival (Fig 3A–3E, 3H–3J). The gene discussed is POLG2; the disease is prostate adenocarcinoma.